CCHR International

10/19/2026

Isn't it time the FDA starts doing its job and warning the public about serious psychiatric drug risks? Or do they always need the UK to act first...

08/31/2026

The hearing on Prozac held in 1991 was not just on SSRI Antidepressants causing su***de, but also violence towards others. This is CCHR’s footage of that hearing. It took the FDA another 13 years to issue the black box on all SSRIs causing su***de. They still have neglected to address violence towards others. Also note the 1991 FDA panels pharma conflicts at the end of video

08/26/2026

And then there's Sejal Shah, A Harvard-affiliated psychiatrist who in her testimony repeated the long-debunked marketing campaign that SSRIs correct a "chemical imbalance" or "lack of serotonin" —apparently never having gotten the memo that this theory was debunked years ago (and which psychiatrists repeatedly claim they don't use anymore). These levels of ignorance and incompetence in the mental health industry are not rare. This is mainstream psychiatry and the mental health industry being exposed for what they are.

08/21/2026

Facts about ADHD drugs—
ADHD drugs such as Ritalin, Concerta, Adderall, Vyvanse, Focalin, Dexedrine, and more carry the FDA’s most severe warning, the black box, for having a “high potential for abuse,” including “addiction.” According to the FDA May, 2023 Drug Safety Communication, “𝗘𝘃𝗲𝗻 𝘄𝗵𝗲𝗻 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻 𝘀𝘁𝗶𝗺𝘂𝗹𝗮𝗻𝘁𝘀 𝗮𝗿𝗲 𝘁𝗮𝗸𝗲𝗻 𝗮𝘀 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗲𝗱 𝗯𝘆 𝗮 𝗵𝗲𝗮𝗹𝘁𝗵 𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹, 𝘁𝗵𝗲𝘆 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗺𝗶𝘀𝘂𝘀𝗲 𝗮𝗻𝗱 𝗮𝗯𝘂𝘀𝗲, 𝗮𝗹𝘀𝗼 𝗰𝗮𝗹𝗹𝗲𝗱 𝗻𝗼𝗻𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.”

The US Drug Enforcement Administration (DEA) classifies drugs into Schedules I–V primarily according their potential for abuse and drug dependence. ADHD drugs are classified as Schedule 2 – prescription drugs which have the highest potential for abuse, and include OxyContin, Fentanyl, Ritalin, Adderall, Dexedrine, Concerta, Vyvanse, Focalin and more.

𝗧𝗵𝗲 𝗗𝗘𝗔 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝘀𝘁𝗮𝘁𝗲𝘀 𝘁𝗵𝗮𝘁 𝘁𝗵𝗲𝘀𝗲 𝗱𝗿𝘂𝗴𝘀 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 “𝘀𝗲𝘃𝗲𝗿𝗲 𝗮𝗻𝗱 𝗽𝘀𝘆𝗰𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝗰𝗲” 𝗮𝗻𝗱 𝗮𝗿𝗲 “𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗲𝗱 𝗱𝗮𝗻𝗴𝗲𝗿𝗼𝘂𝘀.”

Given that data, consider that the CDC estimates 3.7 – 4 million children are currently prescribed ADHD drugs for an ADHD "diagnosis" which is not adjudicated by any medical test, brain scan or confirmatory medical test, but simply a checklist of behaviors. This is why the NIH admits that there is no valid test for ADHD.

08/19/2026

Decades before Britain’s new Channel 4 documentary, "𝗧𝗵𝗲 𝗚𝗿𝗲𝗮𝘁 𝗔𝗗𝗛𝗗 𝗠𝘆𝘁𝗵?" began questioning the validity of the ADHD diagnosis, in the 1990s neurologist Fred Baughman was publicly testifying before governments that ADHD was “a total, 100% fraud.” And the new Channel 4 documentary seems to agree, “It’s certainly not a medical condition as far as I’m concerned,” says the former president of the Royal College of General Practitioners, Dr Iona Heath. And a psychologist asks, “We’re going to look back and think: did we actually put a chemical cosh on an entire developing generation of brains?”
𝗧𝗵𝗲 𝗮𝗻𝘀𝘄𝗲𝗿 𝗶𝘀 𝘆𝗲𝘀. See less

08/18/2026

Finally.... The Great ADHD Myth— “It’s certainly not a medical condition as far as I’m concerned,” says the former president of the Royal College of General Practitioners, Dr Iona Heath. “We’re going to look back and think: did we actually put a chemical cosh on an entire developing generation of brains?” says a neurophysiological psychologist.

“The industry around ADHD is about making money at the cost of the misery of others,” says a former president of the Royal College of Psychiatrists.

Dr Max Pemberton isn’t uncompassionate or especially radical, but he assembles a team of medics whose stance on the condition is clear from the off. This is a documentary that will incense and offend many

08/17/2026

𝗧𝗵𝗲 𝗟𝗶𝗻𝗱𝘀𝗮𝘆 𝗖𝗹𝗮𝗻𝗰𝘆 𝗰𝗮𝘀𝗲 𝗶𝘀 𝗻𝗼𝘁 𝗮𝗻 𝗼𝘂𝘁𝗹𝗶𝗲𝗿. 𝗜𝘁 𝗶𝘀 𝗮 𝘄𝗶𝗻𝗱𝗼𝘄 𝗶𝗻𝘁𝗼 𝗵𝗼𝘄 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝘆 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗼𝗽𝗲𝗿𝗮𝘁𝗲𝘀.

Psychiatrists are now downplaying the polypharmacy of the 𝟭𝟯 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗱𝗿𝘂𝗴𝘀 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗲𝗱 𝘁𝗼 𝗟𝗶𝗻𝗱𝘀𝗮𝘆 𝗖𝗹𝗮𝗻𝗰𝘆 𝗶𝗻 𝗷𝘂𝘀𝘁 𝗳𝗼𝘂𝗿 𝗺𝗼𝗻𝘁𝗵𝘀, 𝗰𝗹𝗮𝗶𝗺𝗶𝗻𝗴 𝗺𝗼𝘀𝘁 𝘄𝗲𝗿𝗲 “𝗹𝗼𝘄-𝗱𝗼𝘀𝗲” 𝗮𝗻𝗱 𝗿𝗮𝗿𝗲𝗹𝘆 𝘁𝗮𝗸𝗲𝗻 𝗮𝗹𝗹 𝗮𝘁 𝗼𝗻𝗰𝗲. This is an attempt to blunt the public’s reaction to the sheer number of drugs she was given once that information became public. 𝗧𝗵𝗲 𝗱𝗲𝗳𝗲𝗻𝘀𝗲 𝗶𝘀 𝘁𝘆𝗽𝗶𝗰𝗮𝗹 𝗼𝗳 𝗺𝗮𝗶𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝘆: ignore the FDA-documented psychological and physical effects of these drugs and the profession’s own minimal standards—standards it routinely fails to meet.

𝗙𝗼𝗿 𝗲𝘅𝗮𝗺𝗽𝗹𝗲, the 2026 American Society of Clinical Psychopharmacology (ASCP) task force—one of the main U.S. organizations psychiatrists are supposed to rely on for the practice of psychopharmacology—states clinicians should begin with monotherapy and that “every time you add a medication, you should stop a medication.” Even Stahl’s Prescriber’s Guide—a practical handbook doctors are supposed to use to switch psychiatric drugs—requires accounting for residual activity and half-lives. That means the doctor must factor in how much of the old drug is still affecting the brain so the patient is not exposed to overlapping or conflicting drug effects, unexpected side effects, or withdrawal while the new drug is being introduced.

𝗧𝗵𝗲𝘀𝗲 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗹𝗼𝘄 𝗯𝗮𝗿𝘀 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝘆 𝘀𝗲𝘁𝘀 𝗳𝗼𝗿 𝗶𝘁𝘀𝗲𝗹𝗳. 𝗜𝗻 𝘁𝗵𝗲 𝗖𝗹𝗮𝗻𝗰𝘆 𝗰𝗮𝘀𝗲, 𝗲𝘃𝗲𝗻 𝘁𝗵𝗲𝘀𝗲 𝗹𝗼𝘄𝗲𝘀𝘁 𝗼𝗳 𝗯𝗮𝗿𝘀 𝘄𝗲𝗿𝗲 𝗶𝗴𝗻𝗼𝗿𝗲𝗱.

𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗙𝗗𝗔 𝗹𝗮𝗯𝗲𝗹𝗶𝗻𝗴 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 𝗵𝗮𝘃𝗲 𝗹𝗼𝗻𝗴 𝗿𝗲𝗰𝗼𝗴𝗻𝗶𝘇𝗲𝗱 𝘁𝗵𝗮𝘁 𝗲𝘃𝗲𝗻 𝗹𝗼𝘄-𝗱𝗼𝘀𝗲 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗱𝗿𝘂𝗴𝘀 𝗰𝗮𝗻 𝗿𝗲𝗾𝘂𝗶𝗿𝗲 𝘄𝗲𝗲𝗸𝘀—𝗼𝗿 𝗹𝗼𝗻𝗴𝗲𝗿—𝘁𝗼 𝘁𝗮𝗽𝗲𝗿 𝗮𝗻𝗱 𝗰𝗹𝗲𝗮𝗿, 𝗹𝗲𝗮𝘃𝗶𝗻𝗴 𝗿𝗲𝘀𝗶𝗱𝘂𝗮𝗹 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝘁𝗵𝗮𝘁 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝘁𝗼 𝗮𝗰𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗯𝗿𝗮𝗶𝗻. In reality, “weeks” is often not long enough. The fact that HHS and SAMHSA are now developing new clinical guidance and training on tapering and deprescribing only confirms what has been known for years: residual effects from these drugs can persist well beyond a few weeks, and current practice has failed to account for it.

With current FDA labeling and clinical guidelines, fluoxetine’s active metabolite can persist for weeks. Short-half-life agents such as paroxetine and venlafaxine are well-known for producing anxiety, irritability, and insomnia during withdrawal. Benzodiazepines can trigger rebound anxiety or paradoxical excitation. SSRIs themselves can cause activation, heightened anxiety, insomnia, emotional blunting, or intrusive thoughts.

When these drugs are piled on in quick succession by multiple uncoordinated prescribers—sertraline, fluoxetine, mirtazapine, trazodone, zolpidem, lorazepam, clonazepam, diazepam, quetiapine, lamotrigine, and others—𝗻𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻 𝗰𝗮𝗻 𝗱𝗶𝘀𝘁𝗶𝗻𝗴𝘂𝗶𝘀𝗵 𝗱𝗿𝘂𝗴 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀, 𝗿𝗲𝘀𝗶𝗱𝘂𝗮𝗹 𝗲𝗳𝗳𝗲𝗰𝘁𝘀, 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹, 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝗼𝗿 𝘁𝗵𝗲 𝘂𝗻𝗱𝗲𝗿𝗹𝘆𝗶𝗻𝗴 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻. The patient’s condition deteriorated under this uncontrolled pattern of one psychiatric drug being piled on after another.

𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗽𝘂𝗯𝗹𝗶𝗰 𝘁𝗿𝗶𝗮𝗹 𝗵𝗮𝘀 𝗲𝘅𝗽𝗼𝘀𝗲𝗱 𝗶𝘀 𝗵𝗼𝘄 𝗶𝗴𝗻𝗼𝗿𝗮𝗻𝘁 𝗺𝗮𝗶𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝘀𝘁𝘀 𝗮𝗿𝗲 𝗼𝗳 𝘄𝗵𝗮𝘁 𝗵𝗮𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗯𝗲𝗲𝗻 𝗽𝘂𝗯𝗹𝗶𝗰𝗹𝘆 𝗽𝗿𝗼𝘃𝗲𝗻 𝗼𝗿 𝗱𝗶𝘀𝗽𝗿𝗼𝘃𝗲𝗻. Dr. Sejal Shah, presented as an “expert” as an Associate Chief at a Harvard-affiliated hospital, explained SSRIs as correcting a “lack of serotonin” in the brain—the debunked chemical imbalance myth that mainstream psychiatry claims to have stopped using decades ago. Yet this Harvard psychiatrist apparently didn’t get the memo.

Or 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝘀𝘁 𝗝𝗲𝗻𝗻𝗶𝗳𝗲𝗿 𝗧𝘂𝗳𝘁𝘀, who claimed the FDA’s black-box warning on antidepressants causing suicidal ideation applied only to children. The actual FDA warning covers adults through age 24. And as common sense would dictate, there is no scientific basis for claiming the risk vanishes the day after a patient’s 24th birthday.

𝗣𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗻𝘂𝗿𝘀𝗲 𝗽𝗿𝗮𝗰𝘁𝗶𝘁𝗶𝗼𝗻𝗲𝗿 𝗥𝗲𝗯𝗲𝗰𝗰𝗮 𝗝𝗼𝗹𝗹𝗼𝘁𝘁𝗮 responded to Clancy’s extreme reaction to Zoloft—48 hours without sleep—by declaring it “unusual” and evidence of possible bipolar disorder, then prescribing the antipsychotic Seroquel. This was not clinical science. It is the same pharmaceutical marketing script engineered in the early 2000s: reframe SSRI-induced agitation and sleeplessness as “unmasked bipolar” so another profitable drug class can be added. Internal Lilly materials trained sales representatives in exactly this diagnostic switch. The company later paid $1.415 billion to settle charges that included illegal off-label promotion of Zyprexa for such uses.

This trial is showing the public that the emperor—psychiatry—has no clothes.

Behind the titles, Harvard affiliations, and talk of chemical imbalances and “unmasked bipolar” sits a profession that runs on behavioral checklists, not science. It shows little interest in ruling out real physical causes—such as thyroid problems in the postpartum period—before prescribing psychiatric drugs. Side effects are rebranded as new disorders and used to justify the next prescription. Drugs are piled on with no reliable way to know what remains in the patient’s system, no required training in how to take people off them safely, and no accountability when the resulting deterioration is labeled a new “mental illness.” This is not an unusual case.

𝗧𝗵𝗶𝘀 𝗶𝘀 𝗺𝗮𝗶𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝘆 𝗶𝗻 𝗲𝘃𝗲𝗿𝘆 𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲: 𝗻𝗼 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝘄𝗼𝗿𝗸𝘂𝗽𝘀 𝗳𝗼𝗿 𝘂𝗻𝗱𝗲𝗿𝗹𝘆𝗶𝗻𝗴 𝗽𝗵𝘆𝘀𝗶𝗰𝗮𝗹 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀—𝗷𝘂𝘀𝘁 𝗹𝗮𝗯𝗲𝗹, 𝗱𝗿𝘂𝗴, 𝗮𝗻𝗱 𝘁𝗵𝗲𝗻 𝗯𝗹𝗮𝗺𝗲 𝘁𝗵𝗲 𝗱𝗮𝗺𝗮𝗴𝗲 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗱𝗿𝘂𝗴𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁’𝘀 ‘𝗱𝗶𝘀𝗲𝗮𝘀𝗲.’”

08/14/2026

𝗗𝗿𝘂𝗴 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀’ “𝗕𝗶𝗽𝗼𝗹𝗮𝗿” 𝗦𝗮𝗹𝗲𝘀 𝗦𝗰𝗿𝗶𝗽𝘁 𝗡𝗼𝘄 𝗣𝗹𝗮𝘆𝗶𝗻𝗴 𝗢𝘂𝘁 𝗶𝗻 𝗖𝗹𝗮𝗻𝗰𝘆 𝗧𝗿𝗶𝗮𝗹

The Lindsay Clancy trial is continuing to bring to light what psychiatry has long operated on: industry-written marketing scripts that turn drug side effects into new diagnoses and more prescriptions.

Psychiatric nurse practitioner Rebecca Jollotta testified that Lindsay Clancy’s extreme reaction to Zoloft—staying awake for 48 hours—was “unusual” and therefore evidence of possible underlying bipolar disorder. On that basis she prescribed the antipsychotic Seroquel — 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝗺𝗮𝗿𝗸𝗲𝘁𝗶𝗻𝗴 𝘀𝗰𝗿𝗶𝗽𝘁 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻𝘃𝗲𝗻𝘁𝗲𝗱 𝘁𝘄𝗼 𝗱𝗲𝗰𝗮𝗱𝗲𝘀 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 𝘁𝗼 𝘀𝗲𝗹𝗹 𝗮𝗻𝘁𝗶𝗽𝘀𝘆𝗰𝗵𝗼𝘁𝗶𝗰𝘀 𝗮𝘀 𝗮 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝘁𝗼 𝗦𝗦𝗥𝗜 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀.

That exact diagnostic switch was manufactured by pharmaceutical companies in the early 2000s. As SSRIs flooded the market, patients who became severely agitated, sleepless for days, racing with thoughts, or plunged into worsening anxiety and emotional numbness on the drugs were handed a new label: unmasked bipolar. In other words, these weren’t side effects from the SSRIs—they were an underlying “bipolar disorder” causing these issues.

𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝗟𝗶𝗹𝗹𝘆 𝗱𝗼𝗰𝘂𝗺𝗲𝗻𝘁𝘀 𝗳𝗿𝗼𝗺 𝟮𝟬𝟬𝟬–𝟮𝟬𝟬𝟮 𝘀𝗵𝗼𝘄 𝘀𝗮𝗹𝗲𝘀 𝗿𝗲𝗽𝘀 𝘁𝗿𝗮𝗶𝗻𝗲𝗱 𝘄𝗶𝘁𝗵 𝘀𝗰𝗿𝗶𝗽𝘁𝗲𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝘀—“𝗗𝗼𝗻𝗻𝗮,” “𝗔𝗻𝗱𝗿𝗲𝗮”—𝗶𝗻 𝘄𝗵𝗶𝗰𝗵 𝗮𝗻𝘅𝗶𝗲𝘁𝘆, 𝗶𝗿𝗿𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝘀𝗹𝗲𝗲𝗽𝗹𝗲𝘀𝘀𝗻𝗲𝘀𝘀, 𝗼𝗿 𝘄𝗼𝗿𝘀𝗲𝗻𝗶𝗻𝗴 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝘀 𝗮𝗳𝘁𝗲𝗿 𝗮𝗻 𝗮𝗻𝘁𝗶𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁 𝘄𝗲𝗿𝗲 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝗻𝗼𝘁 𝗮𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀, 𝗯𝘂𝘁 𝗮𝘀 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗼𝗳 𝗮𝗻 𝘂𝗻𝗱𝗲𝗿𝗹𝘆𝗶𝗻𝗴 𝗯𝗶𝗽𝗼𝗹𝗮𝗿 𝗼𝗿 “𝗰𝗼𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗲𝗱 𝗺𝗼𝗼𝗱” 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿 𝘁𝗵𝗲 𝗮𝗻𝘁𝗶𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁 𝗵𝗮𝗱 𝘂𝗻𝗺𝗮𝘀𝗸𝗲𝗱. 𝗭𝘆𝗽𝗿𝗲𝘅𝗮 𝘄𝗮𝘀 𝘁𝗵𝗲𝗻 𝘀𝗼𝗹𝗱 𝗮𝘀 𝘁𝗵𝗲 𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 “𝗺𝗼𝗼𝗱 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘇𝗲𝗿” 𝗳𝗼𝗿 𝘁𝗵𝗮𝘁 “𝘂𝗻𝗺𝗮𝘀𝗸𝗲𝗱 𝗯𝗶𝗽𝗼𝗹𝗮𝗿.”

This was a deliberate sales pitch. Representatives were instructed to present these patients as having “complicated mood” and to position Zyprexa as the solution. The Department of Justice later charged that this sales-force training and symptom-focused promotion were part of the illegal off-label marketing of Zyprexa.

The same companies that made the antidepressants then sold the next drug to “fix” what the first one caused. Lilly’s 2002 TV ad drove the message home: a high-energy woman shopping and dancing cut to her looking depressed, with the voiceover declaring people with bipolar were being treated only for depression “because depression is only half the story.” Viewers were sent to a Lilly site that steered them toward Zyprexa.

𝗜𝘁 𝘄𝗮𝘀 𝗽𝘂𝗿𝗲 𝗺𝗮𝗿𝗸𝗲𝘁 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻—𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗿𝗲𝗳𝗿𝗮𝗺𝗲𝗱 𝗮𝘀 𝗻𝗲𝘄 𝗱𝗶𝘀𝗲𝗮𝘀𝗲, 𝗼𝗻𝗲 𝗽𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗹𝗲 𝗰𝗹𝗮𝘀𝘀 𝗼𝗳 𝗱𝗿𝘂𝗴𝘀 𝗳𝗲𝗲𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁. In 2009 Eli Lilly paid $1.4 billion to settle charges of illegally promoting Zyprexa for off-label uses including depression and agitation. Other makers of atypical antipsychotics faced similar multimillion- and billion-dollar settlements.

Jollotta was not applying independent science. She was repeating the same marketing logic pharmaceutical companies engineered two decades earlier to turn antidepressant side effects into a pipeline for antipsychotics.

08/13/2026

𝗧𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰 𝘁𝗿𝗶𝗮𝗹 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘁𝗲𝘀𝘁𝗶𝗺𝗼𝗻𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗻𝘂𝗿𝘀𝗲𝘀 𝘄𝗵𝗼 𝘁𝗿𝗲𝗮𝘁𝗲𝗱 𝗟𝗶𝗻𝗱𝘀𝗮𝘆 𝗖𝗹𝗮𝗻𝗰𝘆 𝗵𝗮𝘃𝗲 𝗯𝗿𝗼𝘂𝗴𝗵𝘁 𝗴𝗹𝗼𝗯𝗮𝗹 𝗮𝘁𝘁𝗲𝗻𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲 𝗻𝗲𝗴𝗹𝗶𝗴𝗲𝗻𝘁 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗼𝗳 𝗰𝗮𝗿𝗲 𝘁𝗵𝗮𝘁 𝗶𝘀 𝗿𝗮𝗺𝗽𝗮𝗻𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆.

A primary psychiatrist who never once examined her patient in person and couldn’t be bothered to find out what other drugs were being added to the cocktail of more than a dozen psychiatric drugs she had already prescribed.

Multiple psychiatrists and psychiatric nurses who piled on mind-altering drugs in a matter of months with zero coordination, and who ignored the reports of side effects from Lindsay and her husband while remaining apparently ignorant of the 𝗙𝗗𝗔-𝗱𝗼𝗰𝘂𝗺𝗲𝗻𝘁𝗲𝗱 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗱𝗿𝘂𝗴𝘀 𝘁𝗵𝗲𝘆 𝘄𝗲𝗿𝗲 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴—including aggression, hostility, rage, numbness, intrusive thoughts, and suicidal ideation—choosing instead to escalate the chemical assault.

𝗧𝗵𝗶𝘀 𝗶𝘀 𝗻𝗼𝘁 𝗮𝗻 𝗶𝘀𝗼𝗹𝗮𝘁𝗲𝗱 𝗳𝗮𝗶𝗹𝘂𝗿𝗲—It is the routine product of a system in which psychiatrists almost never check for underlying medical conditions and routinely skip even the most basic and standard work-ups—such as a simple thyroid panel that guidelines explicitly recommend for postpartum patients presenting with these exact symptoms—preferring instead to just say “yes” to drugs. Then, after those drugs produce severe side effects, every complaint from the patient is treated as nothing but a justification to pile on more drugs.

𝗪𝗵𝗲𝗻 𝗴𝗿𝗼𝘀𝘀 𝗻𝗲𝗴𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗸𝗶𝗻𝗱 𝗼𝗰𝗰𝘂𝗿𝘀, 𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗽𝗿𝗮𝗰𝘁𝗶𝘁𝗶𝗼𝗻𝗲𝗿𝘀 𝘀𝗵𝗼𝘂𝗹𝗱 𝗽𝗲𝗿𝗺𝗮𝗻𝗲𝗻𝘁𝗹𝘆 𝗹𝗼𝘀𝗲 𝘁𝗵𝗲𝗶𝗿 𝗹𝗶𝗰𝗲𝗻𝘀𝗲𝘀. That is the bare minimum. They should also face malpractice charges for the catastrophic damage their chemical assaults produce. This case does not merely expose one instance of complete psychiatric failure—it pulls back the curtain on what is common practice in the psychiatry industry, and why it must finally be held to account.